YIH
TVRD

Y-Intercept (HK)’s Tvardi Therapeutics TVRD Stock Holding History

Y-Intercept (HK)’s Portfolio TVRD Stock Details TVRD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-11,520
Closed -$107K – 1901
2024
Q2 		$107K Buy
+11,520
New +$275K 0.01% 1253

Other funds holding TVRD

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
C
Chescapmanager Baltimore, Maryland $1.12B AUM 67.49% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
DGI
Disciplined Growth Investors Minneapolis, Minnesota $4.89B AUM 33.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BNP Paribas Financial Markets
BNP Paribas Financial Markets Paris, France $206B AUM 31.61% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Y-Intercept (HK)'s TVRD Position: Q3 2024 in Review

Y-Intercept (HK) sold out of Tvardi Therapeutics (TVRD) in Q3 2024, closing a stake of 11,520 shares — an estimated $107K sold.

Y-Intercept (HK) first reported a position in TVRD in Q2 2024 and held it in 1 quarter. The position peaked at $107K in Q2 2024. 69 funds tracked by Wall St. Rank hold TVRD as of Q3 2024.

  • Y-Intercept (HK) reported no remaining Tvardi Therapeutics position as of Q3 2024 after selling out during the quarter.
  • Y-Intercept (HK) sold 11,520 Tvardi Therapeutics shares in Q3 2024, an estimated $107K.
  • Y-Intercept (HK) first reported a position in Tvardi Therapeutics in Q2 2024 and held it in 1 quarter.
  • Y-Intercept (HK)'s Tvardi Therapeutics position peaked at $107K in Q2 2024.
  • 69 funds tracked by Wall St. Rank held Tvardi Therapeutics as of Q3 2024.

Based on Y-Intercept (HK)'s 13F filing for Q3 2024, filed 15 Nov 2024.